JP2022535267A - 乾癬を治療および／または予防する方法 - Google Patents

乾癬を治療および／または予防する方法 Download PDF

Info

Publication number
JP2022535267A
JP2022535267A JP2021571835A JP2021571835A JP2022535267A JP 2022535267 A JP2022535267 A JP 2022535267A JP 2021571835 A JP2021571835 A JP 2021571835A JP 2021571835 A JP2021571835 A JP 2021571835A JP 2022535267 A JP2022535267 A JP 2022535267A
Authority
JP
Japan
Prior art keywords
administered
days
subject
methods disclosed
affected area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021571835A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020247706A5 (https=
JP2022535267A5 (https=
Inventor
ジョンソン ユ－ナム ラウ
ウィン カイ チャン
ミン－ファン ルドルフ クワン
Original Assignee
アセネックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセネックス インコーポレイテッド filed Critical アセネックス インコーポレイテッド
Publication of JP2022535267A publication Critical patent/JP2022535267A/ja
Publication of JPWO2020247706A5 publication Critical patent/JPWO2020247706A5/ja
Publication of JP2022535267A5 publication Critical patent/JP2022535267A5/ja
Priority to JP2024199595A priority Critical patent/JP2025032128A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021571835A 2019-06-05 2020-06-05 乾癬を治療および／または予防する方法 Pending JP2022535267A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199595A JP2025032128A (ja) 2019-06-05 2024-11-15 乾癬を治療および／または予防する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857796P 2019-06-05 2019-06-05
US62/857,796 2019-06-05
PCT/US2020/036238 WO2020247706A1 (en) 2019-06-05 2020-06-05 Methods of treating and/or preventing psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199595A Division JP2025032128A (ja) 2019-06-05 2024-11-15 乾癬を治療および／または予防する方法

Publications (3)

Publication Number Publication Date
JP2022535267A true JP2022535267A (ja) 2022-08-05
JPWO2020247706A5 JPWO2020247706A5 (https=) 2023-05-25
JP2022535267A5 JP2022535267A5 (https=) 2023-05-25

Family

ID=73653388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571835A Pending JP2022535267A (ja) 2019-06-05 2020-06-05 乾癬を治療および／または予防する方法
JP2024199595A Pending JP2025032128A (ja) 2019-06-05 2024-11-15 乾癬を治療および／または予防する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199595A Pending JP2025032128A (ja) 2019-06-05 2024-11-15 乾癬を治療および／または予防する方法

Country Status (8)

Country Link
US (1) US20220305021A1 (https=)
EP (1) EP3980021A4 (https=)
JP (2) JP2022535267A (https=)
AU (1) AU2020288640A1 (https=)
CA (1) CA3142477A1 (https=)
IL (1) IL288524A (https=)
TW (1) TW202112379A (https=)
WO (1) WO2020247706A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287436A1 (en) * 2007-05-17 2008-11-20 Hangauer Jr David G Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US20090318450A1 (en) * 2006-12-28 2009-12-24 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US20180042934A1 (en) * 2016-08-12 2018-02-15 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CA2969090C (en) * 2014-12-23 2023-05-02 Novartis Ag Triazolopyrimidine compounds and uses thereof
RU2017134379A (ru) * 2015-03-25 2019-04-03 Новартис Аг Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318450A1 (en) * 2006-12-28 2009-12-24 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US20080287436A1 (en) * 2007-05-17 2008-11-20 Hangauer Jr David G Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US20180042934A1 (en) * 2016-08-12 2018-02-15 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade

Also Published As

Publication number Publication date
TW202112379A (zh) 2021-04-01
EP3980021A1 (en) 2022-04-13
US20220305021A1 (en) 2022-09-29
AU2020288640A1 (en) 2021-12-23
IL288524A (en) 2022-01-01
CA3142477A1 (en) 2020-12-10
EP3980021A4 (en) 2023-06-14
JP2025032128A (ja) 2025-03-11
WO2020247706A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
COOPER et al. Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose
Raborn et al. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study
Nast et al. Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris
Gupta et al. Cyclosporine in the treatment of psoriatic arthritis
Godfrey et al. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine
JP2023015269A (ja) 光線角化症を治療および／または予防する方法
Sheu et al. Dapsone therapy for pustular psoriasis: case series and review of the literature
JP2021073258A (ja) トラジピタントによる治療方法
Perlin et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso‐occlusive crisis
JPH10500678A (ja) 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用
CN112689512B (zh) 用于治疗银屑病的组合物和方法
Levine et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis
CN1327843C (zh) 氟马西尼在用于可卡因依赖治疗药物制备中的应用
de la Brassinne et al. PSORIASIS: STATE OF THE ART 2013: Part II: Therapeutics
JP2022535267A (ja) 乾癬を治療および／または予防する方法
Patil et al. Fundamentals of clinical pharmacology with application for pregnant women
US20240024273A1 (en) Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)proprionate for treatment of diseases
Jose et al. Levamisole in patients with recurrent herpes infection
ŞANDRU et al. PSORIASIS VULGARIS-THERAPY CHOICE ACCORDING TO SEVERITY.
SU1114423A1 (ru) Способ лечени невралгии тройничного нерва
Wingate Transdermal methimazole in the treatment of 16 cats with hyperthyroidism
Soloway Systemic therapy for superficial bladder cancer
Wajid A Comparative Study of the Efficacy and Safety of Topical Calcitriol with Calcitriol and Clobetasol in Chronic Plaque Psoriasis
Koç et al. Multiple widespread warts due to etanercept treatment in a psoriatic patient: a case report
CN121175050A (zh) 用于治疗患有中度至重度慢性手部湿疹的患者的慢性手部湿疹的方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240808

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240822

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241210